Boyang Wang, Immortal Dragons, explains how FDA’s Expedited IND Pilot and research partners could speed serial steps to first-in-human trials compared to China’s 818 Decree.
Boyang Wang
Advertisement
Boyang Wang, Founder of Immortal Dragons
Articles by Boyang Wang
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
What the Olanzapine Depot Approval Means for CMC Teams
3
Q&A: Patient-Centric Drug Development Should Start at Product Definition
4
PharmTech Weekly Roundup—Oct. 8, 2026: CPHI Highlights
5